• Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

    January 3, 2017

    New York, NY – January 3, 2017 – Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office (USPTO) for two patent applications that cover methods of administration for its lead product candidate intravenous (IV) tramadol.

    Click to Download PDF

  • Press Release Title 3

    July 17, 2015

    Press release blurb – expands down accordian style to full story. For more information or business development inquiries, please contact us via email at:

    info@avenuetx.com

  • Press Release Title 4

    July 17, 2015

    Press release blurb – expands down accordian style to full story. For more information or business development inquiries, please contact us via email at:

    info@avenuetx.com

  • CORONADO BIOSCIENCES IN-LICENSES IV TRAMADOL, A PHASE III READY ASSET, FROM REVOGENEX IRELAND LTD.

    February 18, 2015
    Forms Subsidiary to Build Portfolio of Acute Care Products Including IV Tramadol

    New York, NY – February 18, 2015– Coronado Biosciences, Inc. (NASDAQ: CNDO) has obtained an exclusive license to an intravenous (IV) formulation of tramadol for the U.S. market from Revogenex Ireland Ltd, a privately held company in Dublin, Ireland. Coronado has formed a wholly owned subsidiary, Avenue Therapeutics, Inc., to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. Coronado will transfer the Revogenex license to Avenue Therapeutics, Inc. In addition to IV tramadol, Avenue Therapeutics plans to seek additional products.

    Click to Download PDF